Compare · ICCC vs ORKA
ICCC vs ORKA
Side-by-side comparison of ImmuCell Corporation (ICCC) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICCC and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $6.74B, about 75.4x ICCC ($89.4M).
- ORKA has been more active in the news (11 items in the past 4 weeks vs 4 for ICCC).
- ORKA has more recent analyst coverage (11 ratings vs 0 for ICCC).
- Company
- ImmuCell Corporation
- Oruka Therapeutics Inc.
- Price
- -
- -
- Market cap
- $89.4M
- $6.74B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1987
- News (4w)
- 4
- 11
- Recent ratings
- 0
- 11
ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Latest ICCC
- SEC Form 10-Q filed by ImmuCell Corporation
- ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026
- ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results
- President and CEO Te Boekhorst Paul Francis Olivier bought $75,960 worth of shares (8,000 units at $9.49), increasing direct ownership by 82% to 17,785 units (SEC Form 4)
- ImmuCell Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- ImmuCell Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest ORKA
- Chief Commercial Officer Edwards Larry Todd was granted 100,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Edwards Larry Todd
- Oruka Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
- SEC Form S-3 filed by Oruka Therapeutics Inc.
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $782,882 worth of shares (7,000 units at $111.84) as part of a pre-agreed trading plan (SEC Form 4)
- General Counsel Quinlan Paul T exercised 52,000 shares at a strike of $11.60 and sold $5,641,409 worth of shares (52,000 units at $108.49) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 10,000 shares at a strike of $15.69 and sold $1,066,572 worth of shares (10,000 units at $106.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Oruka Therapeutics Inc.
- Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update